Ben Broster has joined fellow prop Cobus Visagie in signing a new Saracens contract. Just days after securing the future of Cobus Visagie, Saracens have tied prop Ben Broster to a new two-year deal.

Corbus Pharmaceuticals has a 52 week low of $9.11 and a 52 week high of $61.90. The stock has a market cap of $119.11 million, a P/E ratio of -2.09 and a beta of 2.63. Institutional Inflows and ...

Riley reduced their price objective on shares of Corbus Pharmaceuticals from $85.00 to $40.00 and set a “buy” rating for the company in a research report on Friday, September 20th.

NORWOOD, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that the ...